Eupraxia Pharmaceuticals Reports Annual Meeting Voting Results

June 6, 2024 - Eupraxia Pharmaceuticals (Eupraxia), a biotechnology company specializing in innovative drug delivery technologies, shared the outcomes of its Annual General and Special Meeting of Shareholders held on June 6, 2024. The meeting featured key decisions and the election of the company's Board of Directors.

Board of Directors Election

Shareholders passed a resolution to elect the six nominees proposed by Eupraxia's management to the Board of Directors. These individuals were listed in the company's Management Information Circular dated May 1, 2024. The newly elected directors will serve until the next annual meeting or until their successors are chosen.

Key Business Resolutions

Several important business items were also addressed during the meeting:

1. Auditor Appointment: Shareholders approved the appointment of KPMG LLP as the auditor for the coming year and authorized the Board to set their remuneration.
2. Stock Option Plan: Approval was given for unallocated entitlements under Eupraxia’s amended and restated stock option plan.
3. Share Consolidation and Subdivision: An amendment to the company's Articles was approved, allowing Eupraxia, through a Board resolution, to consolidate or subdivide any of the company’s shares.

Corporate Focus and Innovations

Eupraxia Pharmaceuticals is dedicated to developing locally delivered, extended-release drugs targeted at areas with high unmet medical needs. The company's proprietary DiffuSphere™ technology aims to enhance drug delivery, offering prolonged effects and minimized side effects. This technology, a polymer-based micro-sphere system, supports various pharmacokinetic profiles and can be adapted for multiple active ingredients and delivery methods.

Clinical Trials and Pipeline Developments

Eupraxia is actively engaged in advancing its clinical pipeline. Recently, the company completed a Phase 2b clinical trial named SPRINGBOARD, evaluating EP-104IAR for knee osteoarthritis pain. The trial successfully met its primary endpoint along with three out of four secondary endpoints.

Expanding its EP-104 platform, Eupraxia initiated the Phase 1b/2a RESOLVE trial to treat Eosinophilic Esophagitis (EoE), a gastrointestinal condition. The company is also developing a range of long-acting formulations for various conditions, including other inflammatory joint diseases and oncology. These candidates are designed to enhance the efficacy and tolerability of currently approved drugs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!